The urokinase system in the pathogenesis of atherosclerosis

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 8-14

  Fuhrman, Bianca ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Atherogenesis; Foam cells; Macrophages; Smooth muscle cells; Urokinase; Vascular remodeling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LIPID; PLATELET DERIVED GROWTH FACTOR RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BINDING AFFINITY; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; GENE OVEREXPRESSION; HUMAN; LIPID STORAGE; MACROPHAGE; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER;

ATHEROSCLEROSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MACROPHAGES; MONOCYTES; OXIDATIVE STRESS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VENTRICULAR REMODELING;

EID: 84859812544     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.044     Document Type: Review

References (79)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(4):e18-e209.
2. Moore K.J., Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145(3):341-355.
3. Stocker R., Keaney J.F. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005, 3:1825-1834.
4. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
5. Fuhrman B., Oiknine J., Aviram M. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL, and affects their secretory properties. Atherosclerosis 1994, 111:65-78.
6. Aviram M., Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol Cell Biochem 1998, 188:149-159.
7. Fuhrman B., Judith O., Keidar S., et al. Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL. Free Radic Biol Med 1997, 23:34-46.
8. Fuhrman B., Volkova N., Aviram M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 2002, 161:307-316.
9. Williams K.J., Tabas I. Lipoprotein retention-and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005, 25(8):1536-1540.
10. Waltz D.A., Fujita R.M., Yang X., et al. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol 2000, 22:316-322.
11. Kienast J., Padro T., Steins M., et al. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost 1998, 79:579-586.
12. Lupu F., Heim D.A., Bachmann F., et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995, 15:1444-1455.
13. Padro T., Emeis J.J., Steins M., Schmid K.W., Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995, 15:893-902.
14. Shen G.X. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. Int J Mol Med 1998, 1(2):399-408.
15. Mazar A.P., Henkin J., Goldfarb R.H. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999, 3(1):15-32.
16. Andreasen P.A., Egelund R., Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57(1):25-40.
17. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12):932-943.
18. Binder B.R., Mihaly J., Prager G.W. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007, 97(3):336-342.
19. D'Alessio S., Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009, 14:4575-4587.
20. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584(9):1923-1930.
21. Kiyan J., Kiyan R., Haller H., Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J 2005, 24(10):1787-1797.
22. Nicholl S.M., Roztocil E., Davies M.G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006, 4(2):101-116.
23. Noda-Heiny H., Daugherty A., Sobel B.E. Augmented urokinase receptor expression in atheroma. Arterioscler Thromb Vasc Biol 1995, 15(1):37-43.
24. Falkenberg M., Tom C., DeYoung M.B., et al. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA 2002, 99(16):10665-10670.
25. Gyöngyösi M., Glogar D., Weidinger F., et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J 2004, 147(1):158-164.
26. Dellas C., Schremmer C., Hasenfuss G., Konstantinides S.V., Schäfer K. Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice. Thromb Haemost 2007, 98(1):220-227.
27. Steins M.B., Padró T., Schwaenen C., et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 2004, 15(5):383-391.
28. Pawlak K., Pawlak D., Myśliwiec M. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients. Thromb Res 2008, 121(4):543-548.
29. Pawlak K., Mysliwiec M., Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res 2008, 122(3):328-335.
30. Olson F.J., Thurison T., Ryndel M., Høyer-Hansen G., Fagerberg B. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem 2010, 43(1-2):124-130.
31. Sehestedt T., Lyngbæk S., Eugen-Olsen J., et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011, 216(1):237-243.
32. Svensson P.A., Olson F.J., Hägg D.A., et al. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int J Mol Med 2008, 22(4):459-464.
33. Moriwaki H., Stempien-Otero A., Kremen M., Cozen A.E., Dichek D.A. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 2004, 95(6):637-644.
34. Cozen A.E., Moriwaki H., Kremen M., et al. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 2004, 109:2129-2135.
35. Krishnan R., Kremen M., Hu J.H., et al. Level of macrophage uPA expression is an important determinant of atherosclerotic lesion growth in Apoe-/- mice. Arterioscler Thromb Vasc Biol 2009, 29(11):1737-1744.
36. Kremen M., Krishnan R., Emery I., et al. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci USA 2008, 105(44):17109-17114.
37. Hu J.H., Du L., Chu T., et al. Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice. Circulation 2010, 121(14):1637-1644.
38. Farris S.D., Hu J.H., Krishnan R., et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 2011, 286(25):22665-22677.
39. May A.E., Schmidt R., Kanse S.M., et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 2002, 100(10):3611-3617.
40. Gu J.M., Johns A., Morser J., et al. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice. J Cell Physiol 2005, 204(1):73-82.
41. Pliyev B.K., Antonova O.A., Menshikov M. Participation of the urokinase-type plasminogen activator receptor (uPAR) in neutrophil transendothelial migration. Mol Immunol 2011, 48(9-10):1168-1177.
42. Menshikov M., Elizarova E., Plakida K., et al. Urokinase upregulates matrix metalloproteinase-9expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 2002, 367(Pt 3):833-839.
43. Menshikov M., Torosyan N., Elizarova E., et al. Urokinase induces matrix metalloproteinase-9/gelatinase B expression in THP-1 monocytes via ERK1/2 and cytosolic phospholipase A2 activation and eicosanoid production. J Vasc Res 2006, 43(5):482-490.
44. Gough P.J., Gomez I.G., Wille P.T., Raines E.W. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 2006, 116(1):59-69.
45. Luikart S., Masri M., Wahl D., et al. Urokinase is required for the formation of mactinin, an alpha-actinin fragment that promotes monocyte/macrophage maturation. Biochim Biophys Acta 2002, 1591(1-3):99-107.
46. Yu H., Maurer F., Medcalf R.L. Plasminogen activator inhibitor type 2: aregulator of monocyte proliferation and differentiation. Blood 2002, 99(8):2810-2818.
47. Fuhrman B., Koren L., Volkova N., et al. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002, 164(1):179-185.
48. Fuhrman B., Shiner M., Volkova N., Aviram M. Cell-induced copper ion-mediated low density lipoprotein oxidation increases during in vivo monocyte-to-macrophage differentiation. Free Radic Biol Med 2004, 37(2):259-271.
49. Fuhrman B., Partoush A., Volkova N., Aviram M. Ox-LDL induces monocyte-to-macrophage differentiation in vivo: possible role for the macrophage colony stimulating factor receptor (M-CSF-R). Atherosclerosis 2008, 196(2):598-607.
50. Shiner M., Fuhrman B., Aviram M. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. Free Radic Biol Med 2004, 37(12):2052-2063.
51. Fuhrman B., Khateeb J., Shiner M., et al. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler Thromb Vasc Biol 2008, 28(7):1361-1367.
52. Fuhrman B., Gantman A., Khateeb J., et al. Urokinase activates macrophage PON2 gene transcription via the PI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFR-beta. Cardiovasc Res 2009, 84(1):145-154.
53. Ohwaki K., Bujo H., Jiang M., et al. A secreted soluble form of LR11, specifically expressed in intimal smooth muscle cells, accelerates formation of lipid-laden macrophages. Arterioscler Thromb Vasc Biol 2007, 27(5):1050-1056.
54. Fuhrman B., Nitzan O., Karry R., et al. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis 2007, 195:e108-e116.
55. Korshunov V.A., Schwartz S.M., Berk B.C. Vascular remodeling: hemodynamic and biochemical mechanisms underlying Glagov's phenomenon. Arterioscler Thromb Vasc Biol 2007, 27(8):1722-1728.
56. Clowes A.W., Clowes M.M., Au Y.P., Reidy M.A., Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990, 67(1):61-67.
57. Tkachuk V.A., Plekhanova O.S., Parfyonova Y.V. Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator. Can J Physiol Pharmacol 2009, 87(4):231-251.
58. Mukhina S., Stepanova V., Traktouev D., et al. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem 2000, 275(22):16450-16458.
59. Stepanova V., Jerke U., Sagach V., et al. Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2. J Biol Chem 2002, 277(12):10265-10272.
60. Goncharova E.A., Vorotnikov A.V., Gracheva E.O., et al. Activation of p38 MAP-kinase and caldesmon phosphorylation are essential for urokinase-induced human smooth muscle cell migration. Biol Chem 2002, 383(1):115-126.
61. Kanse S.M., Benzakour O., Kanthou C., et al. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 1997, 17(11):2848-2854.
62. Plekhanova O.S., Parfyonova Y.V., Bibilashvily RSh, et al. Urokinase plasminogen activator enhances neointima growth and reduces lumen size in injured carotid arteries. J Hypertens 2000, 18(8):1065-1069.
63. Plekhanova O., Parfyonova Y., Bibilashvily R., et al. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms. Atherosclerosis 2001, 159(2):297-306.
64. Nicholl S.M., Roztocil E., Davies M.G. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor. J Vasc Surg 2005, 41(4):672-681.
65. Menshikov M., Plekhanova O., Cai H., et al. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vasc Biol 2006, 26(4):801-807.
66. Plekhanova O.S., Men'shikov M.Y., Bashtrykov P.P., et al. Urokinase induces ROS production in vascular smooth muscle cells. Bull Exp Biol Med 2006, 142:304-307.
67. Plekhanova O., Berk B.C., Bashtrykov P., et al. Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res 2009, 46:177-187.
68. Kusch A., Tkachuk S., Lutter S., et al. Monocyte-expressed urokinase regulates human vascular smooth muscle cell migration in a coculture model. Biol Chem 2002, 383(1):217-221.
69. Kunigal S., Kusch A., Tkachuk N., et al. Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1. Blood 2003, 102(13):4377-4383.
70. Kiian I., Tkachuk N., Haller H., Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost 2003, 89(5):904-914.
71. Kusch A., Tkachuk S., Haller H., et al. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J Biol Chem 2000, 275(50):39466-39473.
72. Patecki M., von Schaewen M., Tkachuk S., et al. Tyk2 mediates effects of urokinase on human vascular smooth muscle cell growth. Biochem Biophys Res Commun 2007, 359(3):679-684.
73. Kiyan J., Haller H., Dumler I. The tyrosine phosphatase SHP-2 controls urokinase-dependent signaling and functions in human vascular smooth muscle cells. Exp Cell Res 2009, 315(6):1029-1039.
74. Kiyan J., Smith G., Haller H., Dumler I. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts. Biochem J 2009, 423(3):343-351.
75. Tkachuk N., Tkachuk S., Patecki M., et al. The tight junction protein ZO-2 and Janus kinase 1 mediate intercellular communications in vascular smooth muscle cells. Biochem Biophys Res Commun 2011, 410(3):531-536.
76. Lamfers M.L., Lardenoye J.H., de Vries M.R., et al. In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI. Gene Ther 2001, 8(7):534-541.
77. Lamfers M.L., Grimbergen J.M., Aalders M.C., et al. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res 2002, 91(10):945-952.
78. Eefting D., Seghers L., Grimbergen J.M., et al. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res 2010, 88(2):367-375.
79. Pillay V., Dass C.R., Choong P.F. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007, 25(1):33-39.